Objective： Response Evaluation Criteria in Solid Tumors （RECIST） guideline version 1.0 （RECIST 1.0） was proposed as a new guideline for evaluating tumor response and has been widely accepted as a standardized mea...Objective： Response Evaluation Criteria in Solid Tumors （RECIST） guideline version 1.0 （RECIST 1.0） was proposed as a new guideline for evaluating tumor response and has been widely accepted as a standardized measure. With a number of issues being raised on RECIST 1.0, however, a revised RECIST guideline version 1.1 （RECIST 1.1） was proposed by the RECIST Working Group in 2009. This study was conducted to compare CT tumor response based on RECIST 1.1 vs. RECIST 1.0 in patients with advanced gastric cancer （AGC）. Methods： We reviewed 61 AGC patients with measurable diseases by RECIST 1.0 who were enrolled in other clinical trials between 2008 and 2010. These patients were retrospectively re-analyzed to determine the concordance between the two response criteria using the κ statistic. Results： The number and sum of tumor diameters of the target lesions by RECIST 1.1 were significantly lower than those by RECIST 1.0 （P〈0.0001）. However, there was excellent agreement in tumor response between RECIST 1.1 and RECIST 1.0 0（κ=0.844）. The overall response rates （ORRs） according to RECIST 1.0 and RECIST 1.1 were 32.7% （20/61） and 34.5% （20/58）, respectively. One patient with partial response （PR） based on RECIST 1.0 was reclassified as stable disease （SD） by RECIST 1.1. Of two patients with SD by RECIST 1.0, one was downgraded to progressive disease and the other was upgraded to PR by RECIST 1.1. Conclusions： RECIST 1.1 provided almost perfect agreement with RECIST 1.0 in the CT assessment of tumor response of AGC.展开更多
Three-dimensional(3D)printing technology,as a novel technical method,can convert conventional computed tomography(CT)or magnetic resonance imaging(MRI)scans to computer-aided design files and develop a 2D spatial stru...Three-dimensional(3D)printing technology,as a novel technical method,can convert conventional computed tomography(CT)or magnetic resonance imaging(MRI)scans to computer-aided design files and develop a 2D spatial structure into a 3D imaging structure.In recent years,the technology has been widely used in numerous areas,including head and neck surgery,orthopedics,and bio-medicinal research.This article uses examples of 3D printed tumor models to develop Response Evaluation Criteria In Solid Tumors(RECIST)standards to evaluate the changes in tumors.RECIST standard is currently recognized as the standard for assessment of chemotherapy.Under the RECIST standard,changes occurring in tumors before and after the surgery,are evaluated.The assessment depends upon a CT evaluation of the changes in the lesions with the largest diameters.In addition,the disease progression and stability of remission is also assessed.Three-dimensional printing technology is more intuitive in the evaluation of changes to human tumors following chemotherapy and targeted therapy.However,a few reports are available.展开更多
文摘Objective： Response Evaluation Criteria in Solid Tumors （RECIST） guideline version 1.0 （RECIST 1.0） was proposed as a new guideline for evaluating tumor response and has been widely accepted as a standardized measure. With a number of issues being raised on RECIST 1.0, however, a revised RECIST guideline version 1.1 （RECIST 1.1） was proposed by the RECIST Working Group in 2009. This study was conducted to compare CT tumor response based on RECIST 1.1 vs. RECIST 1.0 in patients with advanced gastric cancer （AGC）. Methods： We reviewed 61 AGC patients with measurable diseases by RECIST 1.0 who were enrolled in other clinical trials between 2008 and 2010. These patients were retrospectively re-analyzed to determine the concordance between the two response criteria using the κ statistic. Results： The number and sum of tumor diameters of the target lesions by RECIST 1.1 were significantly lower than those by RECIST 1.0 （P〈0.0001）. However, there was excellent agreement in tumor response between RECIST 1.1 and RECIST 1.0 0（κ=0.844）. The overall response rates （ORRs） according to RECIST 1.0 and RECIST 1.1 were 32.7% （20/61） and 34.5% （20/58）, respectively. One patient with partial response （PR） based on RECIST 1.0 was reclassified as stable disease （SD） by RECIST 1.1. Of two patients with SD by RECIST 1.0, one was downgraded to progressive disease and the other was upgraded to PR by RECIST 1.1. Conclusions： RECIST 1.1 provided almost perfect agreement with RECIST 1.0 in the CT assessment of tumor response of AGC.
基金Supported by a grant from the National Natural Science Foundation of China(No.81702622)。
文摘Three-dimensional(3D)printing technology,as a novel technical method,can convert conventional computed tomography(CT)or magnetic resonance imaging(MRI)scans to computer-aided design files and develop a 2D spatial structure into a 3D imaging structure.In recent years,the technology has been widely used in numerous areas,including head and neck surgery,orthopedics,and bio-medicinal research.This article uses examples of 3D printed tumor models to develop Response Evaluation Criteria In Solid Tumors(RECIST)standards to evaluate the changes in tumors.RECIST standard is currently recognized as the standard for assessment of chemotherapy.Under the RECIST standard,changes occurring in tumors before and after the surgery,are evaluated.The assessment depends upon a CT evaluation of the changes in the lesions with the largest diameters.In addition,the disease progression and stability of remission is also assessed.Three-dimensional printing technology is more intuitive in the evaluation of changes to human tumors following chemotherapy and targeted therapy.However,a few reports are available.
